California Pacific Medical Center
- Type
- Teaching hospital
- Where
- SAN FRANCISCO, CA
- Medicare CCN
- 050047
- Received
- $1,529,832 in 132 records, 2022 ($30,845 general, $1,498,987 research)
- Source
- CMS Open Payments search ↗
On this site
- Nonprofit contractor: CALIFORNIA PACIFIC MEDICAL CENTER Fuzzy (name and state)
- Federal award recipient: CALIFORNIA PACIFIC MEDICAL CENTER Fuzzy (name and state)
- Nonprofit: CALIFORNIA PACIFIC MEDICAL CENTER Fuzzy (name and state)
- Patent assignee: CALIFORNIA PACIFIC MEDICAL CENTER Fuzzy (name and state)
- Trademark owner: CALIFORNIA PACIFIC MEDICAL CENTER Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2022 | General payment | 3 | $30,845 |
| 2022 | Research payment | 129 | $1,498,987 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Merck Sharp & Dohme LLC | 11 | $683,748 | 2022 |
| ModernaTX, Inc. | 13 | $434,077 | 2022 |
| Genentech, Inc. | 22 | $186,131 | 2022 |
| Regeneron Pharmaceuticals, Inc. | 21 | $58,805 | 2022 |
| Novocure Inc. | 3 | $50,121 | 2022 |
| Jenavalve Technology, Inc. | 1 | $28,499 | 2022 |
| AstraZeneca UK Limited | 3 | $21,305 | 2022 |
| BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | 2 | $20,803 | 2022 |
| Amgen Inc. | 1 | $9,900 | 2022 |
| AstraZeneca Pharmaceuticals LP | 1 | $9,720 | 2022 |
| UCB SA | 2 | $7,163 | 2022 |
| Medtronic, Inc. | 6 | $6,351 | 2022 |
| Partner Therapeutics, Inc. | 1 | $4,200 | 2022 |
| Alexion Pharmaceuticals, Inc. | 1 | $3,750 | 2022 |
| CSL Behring | 42 | $2,910 | 2022 |
| Chiesi USA, Inc. | 1 | $1,500 | 2022 |
| Siemens Medical Solutions USA, Inc. | 1 | $845 | 2022 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 129 | $1,498,987 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 1 | $28,499 |
| Space rental or facility fees (teaching hospital only) | 1 | $1,500 |
| Gift | 1 | $845 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2022-12-31 | Merck Sharp & Dohme LLC | $238,946 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety andEfficacy of Pembrolizumab MK-3475 and Lenvatini | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $105,369 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | Phase II study of olaparib in combination with pembrolizumab in patients with advanced melanoma with homologous recombin | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $51,713 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab MK-3475 versus placebo after complete resection | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $13,985 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety andEfficacy of Pembrolizumab MK-3475 and Lenvatini | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $13,562 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety andEfficacy of Pembrolizumab MK-3475 and Lenvatini | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $3,994 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab MK-3475 versus placebo after complete resection | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $149 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2022 |
| 2022-12-31 | AstraZeneca UK Limited | $61 | Research payment | In-kind items and services | LYNPARZA Drug, Oncology | Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene BRCA Mutated Ovarian Cancer Patients Who Have | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $3 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab MK-3475 versus placebo after complete resection | 2022 |
| 2022-12-22 | Genentech, Inc. | $68,349 | Research payment | Cash or cash equivalent | OCREVUS Biological, Immunology | A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS | 2022 |
| 2022-12-21 | Regeneron Pharmaceuticals, Inc. | $1,119 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY A | 2022 |
| 2022-12-20 | Genentech, Inc. | $2,000 | Research payment | Cash or cash equivalent | COTELLIC Drug, BioOncology | PHASE IB BELVARAFENIB ALONE AND IN COMBO WITH COBI OR COBI ATEZO IN NRAS M ADV MELANOMA PATIENTS | 2022 |
| 2022-12-19 | Merck Sharp & Dohme LLC | $142,737 | Research payment | Cash or cash equivalent | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety andEfficacy of Pembrolizumab MK-3475 and Lenvatini | 2022 |
| 2022-12-14 | Regeneron Pharmaceuticals, Inc. | $2,000 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY A | 2022 |
| 2022-12-14 | Genentech, Inc. | $54 | Research payment | Cash or cash equivalent | Drug | ABIRATERONE PLUS GDC 0068 OR GDC 0980 IN CRPC | 2022 |
| 2022-12-14 | Genentech, Inc. | $27 | Research payment | Cash or cash equivalent | Drug | ABIRATERONE PLUS GDC 0068 OR GDC 0980 IN CRPC | 2022 |
| 2022-12-14 | Genentech, Inc. | $27 | Research payment | Cash or cash equivalent | Drug | ABIRATERONE PLUS GDC 0068 OR GDC 0980 IN CRPC | 2022 |
| 2022-12-14 | Genentech, Inc. | $27 | Research payment | Cash or cash equivalent | Drug | ABIRATERONE PLUS GDC 0068 OR GDC 0980 IN CRPC | 2022 |
| 2022-12-01 | Alexion Pharmaceuticals, Inc. | $3,750 | Research payment | Cash or cash equivalent | A Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study to Evaluate the Efficacy and Safety of ALXN205 | 2022 | |
| 2022-11-29 | Medtronic, Inc. | $500 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | SMART Trial | 2022 |
| 2022-11-22 | Genentech, Inc. | $4,450 | Research payment | Cash or cash equivalent | OCREVUS Biological, Immunology | A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS | 2022 |
| 2022-11-22 | AstraZeneca UK Limited | $3,500 | Research payment | Cash or cash equivalent | A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib and Doc | 2022 | |
| 2022-11-22 | Regeneron Pharmaceuticals, Inc. | $883 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY A | 2022 |
| 2022-11-21 | CSL Behring | $72 | Research payment | In-kind items and services | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2022 | |
| 2022-11-21 | CSL Behring | $54 | Research payment | In-kind items and services | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2022 | |
| 2022-11-21 | CSL Behring | $36 | Research payment | In-kind items and services | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2022 | |
| 2022-11-21 | CSL Behring | $36 | Research payment | In-kind items and services | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2022 | |
| 2022-11-21 | CSL Behring | $36 | Research payment | In-kind items and services | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2022 | |
| 2022-11-21 | CSL Behring | $36 | Research payment | In-kind items and services | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2022 | |
| 2022-11-15 | Regeneron Pharmaceuticals, Inc. | $1,062 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY A | 2022 |
| 2022-11-08 | Regeneron Pharmaceuticals, Inc. | $1,000 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY A | 2022 |
| 2022-11-07 | Novocure Inc. | $6,512 | Research payment | Cash or cash equivalent | EF-28 Engot -ov50/ INNOVATE-3: Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (TTFields, 200kHz) Concomi | 2022 | |
| 2022-11-03 | Medtronic, Inc. | $1,000 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | Optimize Pro | 2022 |
| 2022-10-28 | ModernaTX, Inc. | $5,115 | Research payment | Cash or cash equivalent | A Phase II randomized study of adjuvant immunotherapy with the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab v | 2022 | |
| 2022-10-12 | Regeneron Pharmaceuticals, Inc. | $1,732 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY A | 2022 |
| 2022-10-06 | Genentech, Inc. | $16,209 | Research payment | Cash or cash equivalent | OCREVUS Biological, Immunology | A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS | 2022 |
| 2022-09-29 | CSL Behring | $207 | Research payment | In-kind items and services | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2022 | |
| 2022-09-29 | CSL Behring | $116 | Research payment | In-kind items and services | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2022 | |
| 2022-09-29 | CSL Behring | $50 | Research payment | In-kind items and services | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2022 | |
| 2022-09-29 | CSL Behring | $28 | Research payment | In-kind items and services | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2022 | |
| 2022-09-29 | CSL Behring | $25 | Research payment | In-kind items and services | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2022 | |
| 2022-09-29 | CSL Behring | $23 | Research payment | In-kind items and services | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2022 | |
| 2022-09-29 | CSL Behring | $16 | Research payment | In-kind items and services | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2022 | |
| 2022-09-29 | CSL Behring | $7 | Research payment | In-kind items and services | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2022 | |
| 2022-09-29 | CSL Behring | $4 | Research payment | In-kind items and services | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2022 | |
| 2022-09-29 | CSL Behring | $3 | Research payment | In-kind items and services | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2022 | |
| 2022-09-23 | ModernaTX, Inc. | $145,344 | Research payment | Cash or cash equivalent | A Phase II randomized study of adjuvant immunotherapy with the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab v | 2022 | |
| 2022-09-23 | UCB SA | $1,424 | Research payment | Cash or cash equivalent | Phase 3, Multicenter, Randomized, Double-Blind, PBO-Controlled Study of Efficacy, Safety, and Tolerability of Zilucoplan | 2022 | |
| 2022-09-20 | Regeneron Pharmaceuticals, Inc. | $1,232 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY A | 2022 |
| 2022-09-19 | Amgen Inc. | $9,900 | Research payment | Cash or cash equivalent | 2022 | ||
| 2022-09-18 | Merck Sharp & Dohme LLC | $7,136 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab MK-3475 versus placebo after complete resection | 2022 |
| 2022-09-14 | Medtronic, Inc. | $475 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | Optimize Pro | 2022 |
| 2022-09-09 | Regeneron Pharmaceuticals, Inc. | $883 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY A | 2022 |
| 2022-09-07 | Genentech, Inc. | $2,750 | Research payment | Cash or cash equivalent | Drug | ABIRATERONE PLUS GDC 0068 OR GDC 0980 IN CRPC | 2022 |
| 2022-09-07 | Genentech, Inc. | $2,700 | Research payment | Cash or cash equivalent | Drug | ABIRATERONE PLUS GDC 0068 OR GDC 0980 IN CRPC | 2022 |
| 2022-09-07 | Genentech, Inc. | $500 | Research payment | Cash or cash equivalent | Drug | ABIRATERONE PLUS GDC 0068 OR GDC 0980 IN CRPC | 2022 |
| 2022-08-09 | Regeneron Pharmaceuticals, Inc. | $1,289 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY A | 2022 |
| 2022-08-02 | UCB SA | $5,738 | Research payment | Cash or cash equivalent | Phase 3, Multicenter, Open-Label Extension Study of Zilucoplan in Subjects with Generalized Myasthenia Gravis | 2022 | |
| 2022-07-27 | ModernaTX, Inc. | $43,132 | Research payment | Cash or cash equivalent | A Phase II randomized study of adjuvant immunotherapy with the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab v | 2022 | |
| 2022-07-21 | Regeneron Pharmaceuticals, Inc. | $940 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY A | 2022 |
| 2022-06-30 | Regeneron Pharmaceuticals, Inc. | $1,232 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY A | 2022 |
| 2022-06-16 | Genentech, Inc. | $49,638 | Research payment | Cash or cash equivalent | OCREVUS Biological, Immunology | A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS | 2022 |
| 2022-06-16 | AstraZeneca Pharmaceuticals LP | $9,720 | Research payment | Cash or cash equivalent | FARXIGA Drug, Cardiovascular and Metabolism | Dapagliflozin in Acute Decompensated Heart Failure | 2022 |
| 2022-06-16 | CSL Behring | $360 | Research payment | In-kind items and services | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2022 | |
| 2022-06-16 | CSL Behring | $180 | Research payment | In-kind items and services | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2022 | |
| 2022-06-16 | CSL Behring | $144 | Research payment | In-kind items and services | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2022 | |
| 2022-06-16 | CSL Behring | $126 | Research payment | In-kind items and services | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2022 | |
| 2022-06-16 | CSL Behring | $126 | Research payment | In-kind items and services | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2022 | |
| 2022-06-16 | CSL Behring | $126 | Research payment | In-kind items and services | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2022 | |
| 2022-06-16 | CSL Behring | $126 | Research payment | In-kind items and services | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2022 | |
| 2022-06-16 | CSL Behring | $120 | Research payment | In-kind items and services | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2022 | |
| 2022-06-16 | CSL Behring | $104 | Research payment | In-kind items and services | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2022 | |
| 2022-06-16 | CSL Behring | $104 | Research payment | In-kind items and services | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2022 | |
| 2022-06-16 | CSL Behring | $52 | Research payment | In-kind items and services | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2022 | |
| 2022-06-16 | CSL Behring | $48 | Research payment | In-kind items and services | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2022 | |
| 2022-06-16 | CSL Behring | $30 | Research payment | In-kind items and services | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2022 | |
| 2022-06-16 | CSL Behring | $18 | Research payment | In-kind items and services | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2022 | |
| 2022-06-16 | CSL Behring | $10 | Research payment | In-kind items and services | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2022 | |
| 2022-06-16 | CSL Behring | $3 | Research payment | In-kind items and services | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2022 | |
| 2022-06-14 | Genentech, Inc. | $4,769 | Research payment | Cash or cash equivalent | COTELLIC Drug, BioOncology | PHASE IB BELVARAFENIB ALONE AND IN COMBO WITH COBI OR COBI ATEZO IN NRAS M ADV MELANOMA PATIENTS | 2022 |
| 2022-06-14 | Genentech, Inc. | $3,781 | Research payment | Cash or cash equivalent | COTELLIC Drug, BioOncology | PHASE IB BELVARAFENIB ALONE AND IN COMBO WITH COBI OR COBI ATEZO IN NRAS M ADV MELANOMA PATIENTS | 2022 |
| 2022-06-14 | Genentech, Inc. | $1,500 | Research payment | Cash or cash equivalent | COTELLIC Drug, BioOncology | PHASE IB BELVARAFENIB ALONE AND IN COMBO WITH COBI OR COBI ATEZO IN NRAS M ADV MELANOMA PATIENTS | 2022 |
| 2022-06-02 | Regeneron Pharmaceuticals, Inc. | $2,173 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY A | 2022 |
| 2022-05-19 | Regeneron Pharmaceuticals, Inc. | $2,288 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY A | 2022 |
| 2022-05-11 | ModernaTX, Inc. | $5,904 | Research payment | Cash or cash equivalent | A Phase II randomized study of adjuvant immunotherapy with the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab v | 2022 | |
| 2022-05-11 | ModernaTX, Inc. | $539 | Research payment | Cash or cash equivalent | A Phase II randomized study of adjuvant immunotherapy with the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab v | 2022 | |
| 2022-05-09 | Merck Sharp & Dohme LLC | $106,150 | Research payment | In-kind items and services | LYNPARZA Biological, ONCOLOGY | Phase II study of olaparib in combination with pembrolizumab in patients with advanced melanoma with homologous recombin | 2022 |
| 2022-05-06 | CSL Behring | $207 | Research payment | In-kind items and services | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2022 | |
| 2022-05-06 | CSL Behring | $116 | Research payment | In-kind items and services | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2022 | |
| 2022-05-06 | CSL Behring | $50 | Research payment | In-kind items and services | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2022 | |
| 2022-05-06 | CSL Behring | $28 | Research payment | In-kind items and services | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2022 | |
| 2022-05-06 | CSL Behring | $25 | Research payment | In-kind items and services | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2022 | |
| 2022-05-06 | CSL Behring | $23 | Research payment | In-kind items and services | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2022 | |
| 2022-05-06 | CSL Behring | $16 | Research payment | In-kind items and services | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2022 | |
| 2022-05-06 | CSL Behring | $7 | Research payment | In-kind items and services | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2022 | |
| 2022-05-06 | CSL Behring | $4 | Research payment | In-kind items and services | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2022 | |
| 2022-05-06 | CSL Behring | $3 | Research payment | In-kind items and services | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2022 | |
| 2022-05-05 | Chiesi USA, Inc. | $1,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | CLEVIPREX Drug, CARDIOVASCULAR | 2022 | |
| 2022-04-27 | Regeneron Pharmaceuticals, Inc. | $2,116 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY A | 2022 |
| 2022-04-15 | ModernaTX, Inc. | $2,733 | Research payment | Cash or cash equivalent | A Phase II randomized study of adjuvant immunotherapy with the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab v | 2022 | |
| 2022-04-13 | ModernaTX, Inc. | $3,200 | Research payment | Cash or cash equivalent | A Phase II randomized study of adjuvant immunotherapy with the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab v | 2022 | |
| 2022-04-13 | ModernaTX, Inc. | $3,000 | Research payment | Cash or cash equivalent | A Phase II randomized study of adjuvant immunotherapy with the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab v | 2022 | |
| 2022-04-13 | Regeneron Pharmaceuticals, Inc. | $1,767 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY A | 2022 |
| 2022-04-13 | ModernaTX, Inc. | $500 | Research payment | Cash or cash equivalent | A Phase II randomized study of adjuvant immunotherapy with the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab v | 2022 | |
| 2022-04-13 | ModernaTX, Inc. | $500 | Research payment | Cash or cash equivalent | A Phase II randomized study of adjuvant immunotherapy with the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab v | 2022 | |
| 2022-04-07 | Regeneron Pharmaceuticals, Inc. | $4,084 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY A | 2022 |
| 2022-03-31 | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | $20,130 | Research payment | Cash or cash equivalent | Healey Platform Trial | 2022 | |
| 2022-03-31 | Siemens Medical Solutions USA, Inc. | $845 | Gift | Cash or cash equivalent | RAPIDPoint 400/405/500 Wash/Waste Cartridge Device, DX - Diagnostics incl. all products and services | 2022 | |
| 2022-03-22 | Genentech, Inc. | $21,206 | Research payment | Cash or cash equivalent | OCREVUS Biological, Immunology | A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS | 2022 |
| 2022-03-17 | Regeneron Pharmaceuticals, Inc. | $2,809 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY A | 2022 |
| 2022-03-11 | Medtronic, Inc. | $1,776 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | Optimize Pro | 2022 |
| 2022-03-10 | Regeneron Pharmaceuticals, Inc. | $4,805 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY A | 2022 |
| 2022-03-10 | Regeneron Pharmaceuticals, Inc. | $1,170 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY A | 2022 |
| 2022-03-03 | Genentech, Inc. | $1,000 | Research payment | Cash or cash equivalent | COTELLIC Drug, BioOncology | PHASE IB BELVARAFENIB ALONE AND IN COMBO WITH COBI OR COBI ATEZO IN NRAS M ADV MELANOMA PATIENTS | 2022 |
| 2022-03-02 | Genentech, Inc. | $2,000 | Research payment | Cash or cash equivalent | COTELLIC Drug, BioOncology | PHASE IB BELVARAFENIB ALONE AND IN COMBO WITH COBI OR COBI ATEZO IN NRAS M ADV MELANOMA PATIENTS | 2022 |
| 2022-03-02 | Genentech, Inc. | $1,439 | Research payment | Cash or cash equivalent | Drug | ABIRATERONE PLUS GDC 0068 OR GDC 0980 IN CRPC | 2022 |
| 2022-02-28 | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | $673 | Research payment | Cash or cash equivalent | Healey Platform Trial | 2022 | |
| 2022-02-22 | Novocure Inc. | $42,020 | Research payment | Cash or cash equivalent | EF-28 Engot -ov50/ INNOVATE-3: Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (TTFields, 200kHz) Concomi | 2022 | |
| 2022-02-14 | AstraZeneca UK Limited | $17,743 | Research payment | Cash or cash equivalent | LYNPARZA Drug, Oncology | Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene BRCA Mutated Ovarian Cancer Patients Who Have | 2022 |
| 2022-02-03 | Regeneron Pharmaceuticals, Inc. | $6,201 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY A | 2022 |
| 2022-02-03 | Partner Therapeutics, Inc. | $4,200 | Research payment | Cash or cash equivalent | LEUKINE Drug, Hematology/Oncology | iLEUK Pulm | 2022 |
| 2022-02-02 | Medtronic, Inc. | $650 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | Optimize Pro | 2022 |
| 2022-01-28 | ModernaTX, Inc. | $19,427 | Research payment | Cash or cash equivalent | A Phase II randomized study of adjuvant immunotherapy with the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab v | 2022 | |
| 2022-01-26 | Genentech, Inc. | $1,705 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | A PHASE III OPEN LABEL RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF ATEZOLIZUMAB IN COMB | 2022 |
| 2022-01-26 | Genentech, Inc. | $1,500 | Research payment | Cash or cash equivalent | Drug | ABIRATERONE PLUS GDC 0068 OR GDC 0980 IN CRPC | 2022 |
| 2022-01-26 | Genentech, Inc. | $500 | Research payment | Cash or cash equivalent | Drug | ABIRATERONE PLUS GDC 0068 OR GDC 0980 IN CRPC | 2022 |
| 2022-01-25 | Novocure Inc. | $1,587 | Research payment | Cash or cash equivalent | EF-28 Engot -ov50/ INNOVATE-3: Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (TTFields, 200kHz) Concomi | 2022 | |
| 2022-01-12 | ModernaTX, Inc. | $163,091 | Research payment | Cash or cash equivalent | A Phase II randomized study of adjuvant immunotherapy with the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab v | 2022 | |
| 2022-01-12 | ModernaTX, Inc. | $41,588 | Research payment | Cash or cash equivalent | A Phase II randomized study of adjuvant immunotherapy with the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab v | 2022 | |
| 2022-01-10 | Jenavalve Technology, Inc. | $28,499 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v (6 payments) | Cash or cash equivalent | JenaValve Pericardial TAVR System Device, Cardiology | 2022 | |
| 2022-01-07 | Regeneron Pharmaceuticals, Inc. | $18,013 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY A | 2022 |
| 2022-01-07 | Medtronic, Inc. | $1,950 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | SMART Trial | 2022 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In San Francisco, CA, county San Francisco County, CA, state California; placed by its city name.
| Measure | Place (city or town) San Francisco, CA | County San Francisco County, CA | State California |
|---|---|---|---|
| Population B01003 | 830,235 | 830,235 | 39,287,377 |
| Population, 2020 census P1 | 873,965 | 873,965 | 39,538,223 |
| Median age B01002 | 40.0 | 40.0 | 37.9 |
| Under 18 B01001 | 13.7% | 13.7% | 22.0% |
| 65 and over B01001 | 17.6% | 17.6% | 15.7% |
| Households B11001 | 363,970 | 363,970 | 13,548,091 |
| Foreign born B05002 | 34.0% | 34.0% | 27.0% |
| Median household income B19013 | $140,970 | $140,970 | $99,122 |
| Median family income B19113 | $171,141 | $171,141 | $113,346 |
| Per capita income B19301 | $92,289 | $92,289 | $49,513 |
| Poverty rate B17001 | 11.2% | 11.2% | 12.0% |
| Unemployment rate B23025 | 6.1% | 6.1% | 6.6% |
| Civilian labor force B23025 | 507,262 | 507,262 | 20,068,466 |
| Mean commute (minutes) B08013 | 30.4 | 30.4 | 28.7 |
| Bachelor's degree or higher B15003 | 60.3% | 60.3% | 37.1% |
| Housing units B25001 | 414,602 | 414,602 | 14,644,735 |
| Owner-occupied B25003 | 38.2% | 38.2% | 55.9% |
| Renters B25003 | 61.8% | 61.8% | 44.1% |
| Median home value B25077 | $1,394,500 | $1,394,500 | $734,700 |
| Median gross rent B25064 | $2,476 | $2,476 | $2,036 |
| White, not Hispanic B03002 | 36.8% | 36.8% | 33.8% |
| Black B03002 | 4.7% | 4.7% | 5.2% |
| Hispanic or Latino B03002 | 16.2% | 16.2% | 40.2% |
| Asian B03002 | 34.9% | 34.9% | 15.3% |
| American Indian and Alaska Native B03002 | 0.2% | 0.2% | 0.3% |
Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in San Francisco, CA.
Comments